Company Profile
Updated: 27-OCT-09Debiopharm S.A.
International Private company
Case postale 5911, Chemin Messidor 5-7, Lausanne, CH-1002 9, Switzerland
()41 021 321 01 11, 41 021 321 01 69 fax, http://www.debio.com
Primary SIC: Commercial Physical & Bio Research, Primary NAICS: Research and Development in the Physical Sciences and Engineering Sciences
Description: Services: Flagship company of the Debiopharm Group, a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates, and develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Ipsen's Decapeptyl[R] 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer.
Business Wire; 11/13/2009; 1612 words; ...the existing Decapeptyl([R])'s ones. France is the first country to...Europe. About Decapeptyl([R]) Debiopharm licensed-in triptorelin from Tulane...triptorelin embonate in Europe and the U.S. The active substance in Decapeptyl...
AMPK Activator Licensing Deal Highlights Successful Collaboration between Boston-based Mercury Therapeutics and CreaGen Biosciences.
Cancer Weekly; 11/10/2009; 1368 words; ...deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership...an exclusive licensing agreement with Debiopharm, SA of Lausanne, Switzerland. According...and cardiovascular disease. Mercury's lead generation platform is based on a...
Curis Reports Third Quarter 2009 Financial Results.(Financial report)
Cancer Weekly; 11/10/2009; 2004 words; ...under the Company's August 2009 license agreement with Debiopharm. Operating expenses...305, the company's lead Hsp90 inhibitor...Under the agreement, Debiopharm has assumed all future...the acceptance of Debiopharm's application to begin...
Other News To Note.
BIOWORLD Today; 11/4/2009; 2590 words; ...to determine whether Celsion's doxorubicin-laden, temperature...the tumor margin by Celsion's heat-activated liposomes will improve therapy. Celsion's drug delivery technology is licensed from Duke University. Debiopharm SA, of Lausanne, Switzerland...
Dyax, AstraZeneca Sign Deal For Phage Display Research.
BIOWORLD Today; 11/4/2009; 938 words; ...AstraZeneca will fund Dyax's part of the research program...story in this issue). "It's sort of ironic," Morgan said...cystic fibrosis, partnered with Debiopharm SA, of Lausanne, Switzerland...and other side effects. Dyax's stock (NASDAQ:DYAX) closed...
Recent News Articles
- Ipsen and Debiopharm Group Announce That Decapeptyl[R] (triptorelin embonate) 6-Month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer.
Business Wire - October 13, 2009 - The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research.
PR Newswire - October 05, 2009 - Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation of the Ipsen's Proprietary CDC-251 Inhibitor (IRC-083864 or Debio 0931) an Anti-Cancer Agent.
Business Wire - September 07, 2009 - Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent.
PR Newswire - September 07, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
